1. Clinical & Scientific Overview
Piroctone Olamine (TIP-MED-000623, Reference Code [COS-19]) is classified under
Cosmetics & Cosmeceutical Ingredients (Cosmetics Rules, 2020) as a Cosmetic Science & Dermopharmaceutics • Hydroxamic Acid Derivative Anti-Dandruff & Scalp Sebum-Regulating Active.
Within the Indian regulatory and compendial framework, it is governed under Permitted cosmetic preservative/anti-dandruff active under IS 4707 / Cosmetics Rules, 2020 (up to 1.0% rinse-off, 0.05–0.1% leave-on); Ketoconazole 2% remains a Schedule H drug shampoo..
INCI Standard: Piroctone Olamine (IS 4707 / Cosmetics Rules, 2020 Compliant)
0.5% to 1.0% in rinse-off shampoos; 0.05% to 0.1% in leave-on scalp tonics; pH 5.5–7.5
Dermopharmaceutics, INCI Formulation & Cosmetics Rules 2020 Compliance
Piroctone OlamineHydroxamic Acid Derivative Anti-Dandruff & Scalp Sebum-Regulating Active
0.5% to 1.0% in rinse-off shampoos; 0.05% to 0.1% in leave-on scalp tonics; pH 5.5–7.5
Irritation, Sensitisation & Photoprotection Considerations: Low scalp irritation and non-sensitising; environmentally and toxicologically preferred alternative to Zinc Pyrithione.
Chemical Stability & Formulation Incompatibilities: Forms coloured complexes with free ferric/ferrous ions in water — always include a chelating agent (disodium EDTA or sodium phytate) and avoid metallic iron manufacturing vessels.
Statutory Cosmetic vs Drug Distinction (Cosmetics Rules, 2020 & BIS IS 4707): Permitted cosmetic preservative/anti-dandruff active under IS 4707 / Cosmetics Rules, 2020 (up to 1.0% rinse-off, 0.05–0.1% leave-on); Ketoconazole 2% remains a Schedule H drug shampoo.
3. Mechanism of Action & Pharmacodynamics
Chelates trivalent iron (Fe3+) and divalent cations required by Malassezia globosa and Malassezia restricta mitochondrial energy metabolism, inhibiting fungal proliferation and scalp free-fatty-acid irritation.
4. Therapeutic Indications & Evidence-Supported Uses
- Cosmetic anti-dandruff shampoos and scalp-conditioning tonics
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Cosmetic Formulation Concentration & pH Window: 0.5% to 1.0% in rinse-off shampoos; 0.05% to 0.1% in leave-on scalp tonics; pH 5.5–7.5
Administration & Meal Timing: External topical use only (0.5% to 1.0% in rinse-off shampoos; 0.05% to 0.1% in leave-on scalp tonics; pH 5.5–7.5). Forms coloured complexes with free ferric/ferrous ions in water — always include a chelating agent (disodium EDTA or sodium phytate) and avoid metallic iron manufacturing vessels.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Stratum corneum partitioning and epidermal retention governed by molecular weight (<500 Da rule), logP, and formulation pH; cosmetic ingredients are formulated for local epidermal/corneocyte conditioning without systemic pharmacological action.
Local epidermal enzymatic hydrolysis or oxidation where applicable (e.g., esterases for retinyl/tocopheryl esters).
Not applicable (topical cosmetic ingredient with negligible systemic exposure when used on intact skin).
Not applicable (topical external cosmetic use).
7. Contraindications, Precautions & High-Risk Warnings
- Known allergic contact dermatitis or hypersensitivity to Piroctone Olamine
- Application to open wounds, abraded skin, or acute infectious dermatoses
- Low scalp irritation and non-sensitising; environmentally and toxicologically preferred alternative to Zinc Pyrithione.
Key Clinical Precautions: Low scalp irritation and non-sensitising; environmentally and toxicologically preferred alternative to Zinc Pyrithione.
8. Adverse Effects Profile
- Low scalp irritation and non-sensitising; environmentally and toxicologically preferred alternative to Zinc Pyrithione.
- Low scalp irritation and non-sensitising; environmentally and toxicologically preferred alternative to Zinc Pyrithione.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Forms coloured complexes with free ferric/ferrous ions in water — always include a chelating agent (disodium EDTA or sodium phytate) and avoid metallic iron manufacturing vessels.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Formulation Stability & Compatibility Check: Forms coloured complexes with free ferric/ferrous ions in water — always include a chelating agent (disodium EDTA or sodium phytate) and avoid metallic iron manufacturing vessels.
Pharmacist Patient Counselling Points:
- Perform a 24–48 hour forearm patch test before introducing a new active cosmeceutical onto facial skin.
- Apply broad-spectrum SPF 30+ PA+++ sunscreen every morning, especially when using AHAs, BHAs, retinol, or brightening actives.
- Cosmetic products clean, condition, or protect superficial skin appearance; persistent acne, melasma, rosacea, or eczema requires medical dermatology evaluation.
Storage, Stability & Dispensing Safeguards: Forms coloured complexes with free ferric/ferrous ions in water — always include a chelating agent (disodium EDTA or sodium phytate) and avoid metallic iron manufacturing vessels.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Cosmetics Rules, 2020 (CDSCO, Ministry of Health & Family Welfare, Govt. of India); Bureau of Indian Standards (BIS) IS 4707 (Part 1 & Part 2) Classification of Cosmetic Raw Materials and Adjuncts.
Official Verification Portals: CDSCO — Cosmetics Division & Cosmetics Rules, 2020 • Bureau of Indian Standards (BIS) — IS 4707 Cosmetic Standards
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.